These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 16737009)

  • 61. The defined daily dose as a tool in pharmacoeconomics. Advantages and limitations.
    Clarke KW; Gray D
    Pharmacoeconomics; 1995 Apr; 7(4):280-3. PubMed ID: 10155317
    [No Abstract]   [Full Text] [Related]  

  • 62. Clinical and economic considerations of coronary heart disease: a managed care approach. Proceedings based on presentations from two conferences, Cardiovascular Event Reduction: Defining the Role of HMG Therapy in Managed Care, held November 14-16, 1997 in Philadelphia, and Pharmacoeconomics & Outcomes Issues of Lipid Therapy, held November 5-7, 1997 in Orlando.
    Am J Manag Care; 1998 Apr; 4(4 Suppl):S168-233. PubMed ID: 10180343
    [No Abstract]   [Full Text] [Related]  

  • 63. The role of pharmacoeconomics in health policy and management in Norway.
    Grund J; Husbyn H
    Pharmacoeconomics; 1995 Jun; 7(6):475-83. PubMed ID: 10155333
    [No Abstract]   [Full Text] [Related]  

  • 64. [Pharmacoeconomics in cardiovascular disease. Part 1: pharmacoeconomics in coronary heart disease].
    Wozakowska-Kapłon B; Kempkiewicz T
    Pol Arch Med Wewn; 2003 Nov; 110(5):1367-73. PubMed ID: 16737009
    [No Abstract]   [Full Text] [Related]  

  • 65. [Pharmacoeconomics in cardiovascular disease. Part 2: pharmacoeconomics in congestive heart failure and arterial hypertension].
    Wozakowska-Kapłon B; Kempkiewicz T
    Pol Arch Med Wewn; 2003 Nov; 110(5):1375-8. PubMed ID: 16737010
    [No Abstract]   [Full Text] [Related]  

  • 66. [Pharmacoeconomics of dyspesia and peptic ulcer disease].
    Kusowska J
    Pol Merkur Lekarski; 2006 Jan; 20(115):125-8. PubMed ID: 16617753
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Burden of coronary heart disease in India.
    Gupta R
    Indian Heart J; 2005; 57(6):632-8. PubMed ID: 16521628
    [No Abstract]   [Full Text] [Related]  

  • 68. Ischemic burden, treatment allocation, and outcomes in stable coronary artery disease.
    Farzaneh-Far A; Borges-Neto S
    Circ Cardiovasc Imaging; 2011 Nov; 4(6):746-53. PubMed ID: 22086945
    [No Abstract]   [Full Text] [Related]  

  • 69. Overview of the pharmacoeconomics of pharmacogenetics.
    Dervieux T; Bala MV
    Pharmacogenomics; 2006 Dec; 7(8):1175-84. PubMed ID: 17184205
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Use of pharmacoeconomics analyses to health protection].
    Drozd M
    Wiad Lek; 2002; 55 Suppl 1():76-9. PubMed ID: 15002222
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A note in support of reversal treatment for coronary artery disease.
    Lane DM
    J Okla State Med Assoc; 1995 Apr; 88(4):165-7. PubMed ID: 7782964
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cost-effectiveness of accepted measures for intervention in coronary heart disease.
    Kuntz KM; Lee TH
    Coron Artery Dis; 1995 Jun; 6(6):472-8. PubMed ID: 7551268
    [No Abstract]   [Full Text] [Related]  

  • 73. [Cost analysis of percutaneous coronary intervention and coronary artery bypass grafting in Japan and USA].
    Chino M; Sasaki T
    Nihon Rinsho; 2003 Apr; 61 Suppl 4():632-7. PubMed ID: 12735043
    [No Abstract]   [Full Text] [Related]  

  • 74.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.